Amicus Therapeutics, a clinical-stage biopharmaceutical company focused on therapeutics for diseases caused by misfolding proteins, filed for IPO Friday. Morgan Stanley and Merrill Lynch are the lead underwriters the deal. Terms have not yet been announced.
